The present application is a 371 U.S. National Phase of PCT/FR2008/050419, filed Mar. 12, 2008, which designated the U.S. and claims benefit of FR 0753787, filed Mar. 13, 2007.
The present invention generally relates to devices for epi- or trans-cutaneous application of biologically active substances. The invention more particularly relates to transdermal devices or patches intended to facilitate cutaneous absorption of such substances, notably for vaccination, desensitization or drug administration purposes.
The human epidermis forms a barrier against the entry of exterior agents into the body. The skin is not impervious, but in fact pervious to a very large number of substances with variable permeability level.
Percutaneous absorption corresponds to the transfer of a substance through the skin from the exterior medium as far as the blood. This absorption is defined as the sum of two phenomena: a penetration of molecules into the interior of the entire skin, followed by resorption by the blood or lymph circulatory flow from the papillar dermis and then from the deep dermis. The penetration step physically is a passive diffusion through each structure of the tegument: the stratum corneum, Malpighi's epidermis, the dermis and cutaneous annexes. Once it is absorbed, the substance is distributed into the body, and then, after having either been metabolized or not, it is eliminated. The steps succeeding to percutaneous absorption are similar to those encountered for any other contamination route.
The stratum corneum is the most effective barrier against the penetration of a substance; anatomically, the substance may penetrate through two routes: one through the intercellular spaces of the stratum corneum and through the corneous cells themselves, the other one via the cutaneous annexes. In the case of a vaccine, once this stratum corneum is crossed, the substance is able to encounter immunologically competent cells, and in particular cells exhibiting antigens such as Langerhans cells, the role of which is primordial in the immunological reaction of the organism. By facilitating the initial passage of the antigen through the stratum corneum, epicutaneous vaccination is made more effective. In the case of a patch intended for administering a molecule for a systemic treatment, by temporarily reducing the effectiveness of the stratum corneum as a barrier, it is possible to open the route to transcutaneous administration of active ingredients with high molecular weights, and generally improve the administration rate of active ingredients.
Percutaneous absorption of a substance by means of a patch has significant advantages relatively to a needle injection: absence of any risk of contamination by damaging the skin, absence of pain, ease in transport, prolonged preservation of the active substance or further administration of the substance by the patient himself/herself.
However, such an administration mode also has drawbacks. Indeed, unlike a sub-cutaneous injection, a minimum period of application is required in order to end up with the effect of the substance of the patch. Thus, vaccination or immunization may be incomplete if the patch has not been applied for sufficient time on the skin. As the required period of application is much longer than the duration of an injection, a practitioner cannot remain close to the patient for this duration. The practitioner is then not quite sure that the patient has kept the patch in contact with the skin for a sufficient time.
Patent FR 2,527,450 relates to a device for releasing a substance in the skin, consisting of, for example, an elastomeric bracelet loaded with an active substance. However, the proposed device is reusable and is therefore not able to prevent early removal of the patch, or to ensure that a sufficient contact time was observed by the patient.
The invention aims at solving one or more of these drawbacks. The object of the invention is thus a device for cutaneous application of a substance, comprising:
The invention thus proposes a device for cutaneously applying a substance making it possible, by a single-use irreversible attachment system, to prevent early removal of the device by the patient and/or to ensure that a sufficient time of contact with the skin has been observed.
According to one alternative, the bracelet comprises two attachment portions and the irreversible attachment system of the bracelet comprises means for attaching together both attachment portions irreversibly, the bracelet forming a loop when both attachment portions are joined together.
According to another alternative, the attachment portions comprise mutually adhesive surfaces.
According to still another alternative:
According to still another alternative, the locking member has a ring delimiting the bore and elastically deformable so as to allow irreversible insertion of the stud.
According to an alternative, the device comprises means for securing the patch to the bracelet.
According to still another alternative, the means for securing the patch to the bracelet are irreversible.
According to another alternative, the irreversible securing means comprise a surface of the patch or bracelet coated with an adhesive and covered with a peelable protective element.
According to a further alternative, the irreversible securing means of the patch to the bracelet comprise a member of the patch and a member of the bracelet which may be snapped on mutually.
According to still another alternative, the device comprises a packaging containing the bracelet and the patch.
According to an alternative, the bracelet has a surface in contact with the substance.
According to a further alternative, the bracelet has an adhesive surface in proximity to the substance.
According to another alternative, the adhesive surface surrounds the substance.
According to still another alternative, the patch comprises a support provided with a face having a surface in contact with the substance and an adhesive surface intended to enter into contact with the skin.
According to an alternative, the patch comprises a peelable protective element if necessary secured to the support or the bracelet and covering the substance.
According to a further alternative, the bracelet covers the substance.
Another object of the invention relates to the use of a device as defined hereinbefore for applying a substance on the skin and/or for delivering a substance via an epi- or trans-cutaneous route to a subject, notably a mammal, in particular a human being (a child or an adult for example). The device may notably be used for vaccinating subjects, for desensitizing subjects, for testing the sensitivity of subjects to substances or for delivering any active substance, such as notably biologically active and/or antigenic (poly)peptides, for example.
The device may also be used for vaccinating subjects against any pathogen. Thus, a particular object of the invention lies in a method for vaccinating a subject against a pathogen, comprising (i) the application of the device according to the invention on the skin of a subject, the substance comprising a specific antigen of said pathogen, (ii) the irreversible attachment of the bracelet around a limb of the subject and the maintaining of the bracelet, preferably at the same location, for a time period allowing transfer of the antigen into the body. The pathogen may be of variable nature (virus, bacteria, parasite, etc.) and the antigen is typically of a polypeptide or lipid nature.
The device may also be used for desensitization of subjects to allergens. Thus, a particular object of the invention lies in a method for desensitizing a subject to an allergen, comprising (i) the application of a device according to the invention on the skin of a subject, the substance comprising a specific antigen of said allergen, (ii) the irreversible attachment of the bracelet around a limb of the subject and the maintaining of the bracelet, preferably at the same location, for a time period allowing transfer of the antigen into the skin.
The device may also be used for delivering any active substance. Thus, a particular object of the invention lies in a method for delivering an active substance to a subject, comprising (i) the application of a device according to the invention on the skin of a subject, the substance comprising a specific antigen of said allergen, (ii) the irreversible attachment of the bracelet around a limb of the subject and the maintaining of the bracelet, preferably at a the same location, for a time period allowing transfer of the substance into the skin. The substance is typically of a polypeptide nature, such as a hormone, a cytokine, a growth factor, a trophic factor, etc.
The substance contained in the patch may be formulated in any suitable carrier or excipient, and may be in solid form (powder), liquid form (for example a gel, slurry, solution), etc.
Another object of the invention relates to a method for making a device as defined above, comprising a step of functional assembling between a patch and a single-use bracelet with irreversible attachment.
Other features and advantages of the invention will become clearly apparent from the description which is made thereof hereafter, as an indication and by no means as a limitation, with reference to the appended drawings, wherein:
Subsequently, the terms of irreversible or untamperable attachment will define an attachment which has to be at least partly destroyed in order to be undone.
The invention proposes a device for cutaneously applying a substance, making it possible to determine or ensure with certainty that a substance has been applied for a sufficiently long time. The device comprises a patch including said substance intended to penetrate or enter into contact with the epidermis, and a single-use bracelet provided with an irreversible attachment system with which it is possible to avoid early removal of the device and/or ensure that a sufficient contact time of the substance against the skin of a subject has been observed.
The patch may be of any nature, and it may thus be any device or any support or surface applied on the skin of a subject in order to apply a substance thereon. This may be a patch, either occlusive or not, a transdermal device, a bandage, etc. The patch may consist of different materials (polymer(s), plastic, metal, patch, etc.), and the substance may be bound to the patch in different ways (impregnation, covalent bond, reservoir, electrostatic forces, etc.).
The bracelet 4 is substantially formed as a strip. The bracelet 4 comprises in a known way per se, two attachment portions 41 and 42, positioned on both ends of the strip. In a known way per se, the bracelet 4 is flexible so that the attachment portions 41 and 42 may be joined together. When the attachment portions 41 and 42 are joined together, the bracelet 4 forms a loop, as illustrated in
The ring 52 is positioned on a side protrusion of the portion 41. This side protrusion 43 is able to be folded back in order to insert the stud 51 into the bore 53 of the ring 52. The attachment portion 42 comprises several bores 54 distributed in the direction of the length of the bracelet 4. The different longitudinal positions of the bores allow the size of the loop to be adapted to the dimension of the limb of the subject. As illustrated in
Other irreversible attachment means of the attachment portions known to one skilled in the art in the field of untamperable bracelets may of course be used.
As illustrated in
In this embodiment, the provided device initially comprises a patch 3 integral with the bracelet 4. The bracelet 4 in practice forms a support in contact with the adhesive 31 and the substance 2. Irreversibility of the attachment therefore guarantees application on the skin of the substance 2 of the patch until failure of the bracelet 4 or of the attachment system.
As a replacement or in addition to the irreversible mechanical attachment by means of the elements 51-54, it is also possible to contemplate both portions 41 and 42 having mutually adhesive surfaces. The person skilled in the art may determine an adequate adhesive so that an attempt to open the loop leads to visible deterioration of the bracelet or of the adhesive.
In the embodiments of
The device 1 according to the embodiment illustrated in
A peelable protective element 6 entirely covers the adhesive 31 and the substance 2. A peelable protective element 7 entirely covers the adhesive 33, in order to avoid its deterioration before its application against the bracelet 4. Like the peelable element 6, the peelable element 7 has a grip member for facilitating its peeling.
The device 1 according to the embodiment illustrated in
In the embodiments of
Number | Date | Country | Kind |
---|---|---|---|
07 53787 | Mar 2007 | FR | national |
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/FR2008/050419 | 3/12/2008 | WO | 00 | 3/22/2010 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2008/132358 | 11/6/2008 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
153439 | Juergenson | Jul 1874 | A |
432798 | Hirst | Jul 1890 | A |
588091 | Sanche | Aug 1897 | A |
953818 | Chambers | Apr 1910 | A |
1081148 | Quayle | Dec 1913 | A |
1093743 | Tegarden | Apr 1914 | A |
1780407 | Smith | Nov 1930 | A |
2138040 | Perry | Nov 1938 | A |
2288745 | Sammis | Jul 1942 | A |
2641074 | Richmond | Jun 1953 | A |
3212495 | Osbourn et al. | Oct 1965 | A |
3491753 | Milton | Jan 1970 | A |
3598122 | Zaffaroni | Aug 1971 | A |
3886935 | Sprague | Jun 1975 | A |
3996934 | Zaffaroni | Dec 1976 | A |
4031859 | Stewart | Jun 1977 | A |
4140116 | Hampicke | Feb 1979 | A |
4297995 | Golub | Nov 1981 | A |
4430961 | Steckel | Feb 1984 | A |
4435180 | Leeper | Mar 1984 | A |
4450844 | Quisno | May 1984 | A |
4486194 | Ferrara | Dec 1984 | A |
4592753 | Panoz | Jun 1986 | A |
4595011 | Phillips | Jun 1986 | A |
4619654 | Abplanalp | Oct 1986 | A |
4620849 | Corner | Nov 1986 | A |
4666441 | Andriola et al. | May 1987 | A |
4781705 | Shepherd et al. | Nov 1988 | A |
4833807 | McLean | May 1989 | A |
5135480 | Bannon et al. | Aug 1992 | A |
5167617 | Sibalis | Dec 1992 | A |
5194265 | Boettcher et al. | Mar 1993 | A |
5259835 | Clark et al. | Nov 1993 | A |
5396901 | Phillips | Mar 1995 | A |
5448846 | Peterson et al. | Sep 1995 | A |
5507721 | Shippert | Apr 1996 | A |
5591123 | Sibalis et al. | Jan 1997 | A |
5785354 | Haas | Jul 1998 | A |
5899875 | Millot et al. | May 1999 | A |
5914197 | Goudjil | Jun 1999 | A |
6056729 | Yu et al. | May 2000 | A |
6167302 | Millot | Dec 2000 | A |
6349493 | Newman et al. | Feb 2002 | B1 |
6693543 | Stephenson et al. | Feb 2004 | B1 |
7658027 | Jain et al. | Feb 2010 | B2 |
7905111 | Saltz | Mar 2011 | B2 |
20020173738 | Rogalski | Nov 2002 | A1 |
20030114475 | Fox et al. | Jun 2003 | A1 |
20040092896 | Thompson | May 2004 | A1 |
20040189470 | Girvin et al. | Sep 2004 | A1 |
20070156076 | Jackson et al. | Jul 2007 | A1 |
20070248635 | Jensen | Oct 2007 | A1 |
20090118685 | Choi et al. | May 2009 | A1 |
20110004169 | Smith et al. | Jan 2011 | A1 |
Number | Date | Country |
---|---|---|
2527450 | Dec 1983 | FR |
2004052425 | Jun 2004 | WO |
Number | Date | Country | |
---|---|---|---|
20110046578 A1 | Feb 2011 | US |